FOLH1 and prostate cancer: SBRT without ADT for PSMA PET detected oligometastatic prostate cancer in our cohort conferred a 15% 5-year biochemical failure free survival (nadir + 0.2ug/L definition), with 55% of patients not requiring palliative ADT before 5 years.